154 related articles for article (PubMed ID: 30034278)
21. Additional lesions detected in therapeutic scans with 177Lu-DOTATATE reflect higher affinity of 177Lu-DOTATATE for somatostatin receptors.
Mirzaei S; Bastati B; Lipp RW; Knoll P; Zojer N; Ludwig H
Oncology; 2011; 80(5-6):326-9. PubMed ID: 21791941
[TBL] [Abstract][Full Text] [Related]
22. 99mTc-HYNIC-TOC scintigraphy is superior to 131I-MIBG imaging in the evaluation of extraadrenal pheochromocytoma.
Chen L; Li F; Zhuang H; Jing H; Du Y; Zeng Z
J Nucl Med; 2009 Mar; 50(3):397-400. PubMed ID: 19223405
[TBL] [Abstract][Full Text] [Related]
23. Clinical validation and diagnostic accuracy of
Moriguchi-Jeckel CM; Madke RR; Radaelli G; Viana A; Nabinger P; Fernandes B; Gössling G; Berdichevski EH; Vilas E; Giacomazzi J; Rocha MS; Borges JA; Hoffmann E; Greggio S; Venturin GT; Barrios CH; Zaffaroni F; Werutsky G; da Costa JC
Ecancermedicalscience; 2023; 17():1582. PubMed ID: 37533941
[No Abstract] [Full Text] [Related]
24. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
Jois B; Asopa R; Basu S
Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR
J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
[TBL] [Abstract][Full Text] [Related]
26. Clinical utility of indigenously formulated single-vial lyophilized HYNIC-TOC kit in evaluating Gastro-entero Pancreatic neuro endocrine tumours.
Shinto AS; Kamaleshwaran K; Vyshak K; Sudhakar N; Banerjee S; Korde A; Samuel G; Mallia M
Asia Ocean J Nucl Med Biol; 2014; 2(1):30-41. PubMed ID: 27408857
[TBL] [Abstract][Full Text] [Related]
27. Studies on batch formulation of a freeze dried kit for the preparation of
Mukherjee A; Korde A; Shinto A; Sarma HD; Kamaleswaran K; Dash A
Appl Radiat Isot; 2019 Mar; 145():180-186. PubMed ID: 30639635
[TBL] [Abstract][Full Text] [Related]
28. Comparative analysis of 99mTc-depreotide and 99mTc-EDDA/HYNIC-TOC thorax scintigrams acquired for the purpose of differential diagnosis of solitary pulmonary nodules.
Płachcińska A; Mikołajczak R; Kozak J; Rzeszutek K; Kuśmierek J
Nucl Med Rev Cent East Eur; 2006; 9(1):24-9. PubMed ID: 16791800
[TBL] [Abstract][Full Text] [Related]
29. 99mTc-HYNIC-TOC imaging in the evaluation of pancreatic masses which are potential neuroendocrine tumors.
Qiao Z; Zhang J; Jin X; Huo L; Zhu Z; Xing H; Li F
Clin Nucl Med; 2015 May; 40(5):397-400. PubMed ID: 25706799
[TBL] [Abstract][Full Text] [Related]
30. Clinical application of
Xu J; Li Y; Xu X; Zhang J; Zhang Y; Yu X; Huang D
Ann Nucl Med; 2018 Aug; 32(7):446-452. PubMed ID: 29926342
[TBL] [Abstract][Full Text] [Related]
31. Specificity and sensitivity of ⁹⁹mTc-EDDA/HYNIC-Tyr³-octreotide (⁹⁹mTc-TOC) for imaging neuroendocrine tumors.
Sepúlveda-Méndez J; de Murphy CA; Pedraza-López M; Murphy-Stack E; Rojas-Bautista JC; González-Treviño O
Nucl Med Commun; 2012 Jan; 33(1):69-79. PubMed ID: 21970835
[TBL] [Abstract][Full Text] [Related]
32. Patient-specific dosimetry of
Hou X; Birkenfeld B; Piwowarska-Bilska H; Celler A
EJNMMI Phys; 2017 Oct; 4(1):24. PubMed ID: 29030760
[TBL] [Abstract][Full Text] [Related]
33. Influence of PET/CT 68Ga somatostatin receptor imaging on proceeding with patients, who were previously diagnosed with 99mTc-EDDA/HYNIC-TOC SPECT.
Madrzak D; Mikołajczak R; Kamiński G
Nucl Med Rev Cent East Eur; 2016; 19(2):88-92. PubMed ID: 27479886
[TBL] [Abstract][Full Text] [Related]
34. Value of Somatostatin Receptor Scintigraphy with
Anzola LK; Rivera JN; Dierckx RA; Lauri C; Valabrega S; Galli F; Moreno Lopez S; Glaudemans AWJM; Signore A
J Clin Med; 2019 May; 8(6):. PubMed ID: 31151155
[TBL] [Abstract][Full Text] [Related]
35. Radiolabeled new somatostatin analogs conjugated to DOMA chelator used as targeted tumor imaging agent: synthesis and radiobiological evaluation.
De K; Banerjee I; Misra M
Amino Acids; 2015 Jun; 47(6):1135-53. PubMed ID: 25743164
[TBL] [Abstract][Full Text] [Related]
36. The New Radiolabeled Peptide
Gherghe M; Lazăr AM; Stanciu AE; Mutuleanu MD; Sterea MC; Petroiu C; Galeș LN
Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681704
[TBL] [Abstract][Full Text] [Related]
37. Predictive Value of 99MTC-hynic-toc Scintigraphy in Lung Neuroendocrine Tumor Diagnosis.
Boutsikou E; Porpodis K; Chatzipavlidou V; Hardavella G; Gerasimou G; Domvri K; Papadopoulos N; Avramidou V; Spyratos D; Kontakiotis T; Zarogoulidis K
Technol Cancer Res Treat; 2019 Jan; 18():1533033819842586. PubMed ID: 31079574
[TBL] [Abstract][Full Text] [Related]
38. [99mTc-OCTREOTIDE in patients with neuroendocrine tumors from the GI tract].
Gómez M; Ferrando R; Vilar J; Hitateguy R; López B; Moreira E; Kapitán M; De Lima F; Agüero B; Gabriela Villegas M; Urdaneta N; Gutiérrez E; Battegazzore A; Bayardo K; Silveira A; Lago G; Páez A
Acta Gastroenterol Latinoam; 2010 Dec; 40(4):332-8. PubMed ID: 21381408
[TBL] [Abstract][Full Text] [Related]
39. SPECT Imaging of SST2-Expressing Tumors with
Gaonkar RH; Wiesmann F; Del Pozzo L; McDougall L; Zanger S; Mikołajczak R; Mansi R; Fani M
Pharmaceuticals (Basel); 2021 Mar; 14(4):. PubMed ID: 33800582
[TBL] [Abstract][Full Text] [Related]
40. Utility of (99m)Tc-Hynic-TOC in 131I Whole-Body Scan Negative Thyroid Cancer Patients with Elevated Serum Thyroglobulin Levels.
Shinto AS; Kamaleshwaran KK; Mallia M; Korde A; Samuel G; Banerjee S; Velayutham P; Damodharan S; Sairam M
World J Nucl Med; 2015; 14(2):101-8. PubMed ID: 26097420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
